Belgium· BE-AMP-SAM487777-00
Praxbind 2.5 g/50 ml
A idarucizumab product containing idarucizumab, registered in Belgium by Boehringer Ingelheim International. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Idarucizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC V03AB37 (idarucizumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Idarucizumab · ATC V03AB37
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Idarucizumab
- Manufacturer
- Boehringer Ingelheim International
- Country
- Belgium (BE)
- ATC code
- V03AB37
- ATC class
- Idarucizumab
- Defined daily dose
- 5 g, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb7716301
- be_apb3381555
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Idarucizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPRAXBINDBoehringer Ingelheim International GmbH, Ingelheim am Rhein
- SpainPRAXBIND 2.5 G/50 ML SOLUCION INYECTABLE Y PARA PERFUSIONBoehringer Ingelheim International Gmbh
- FinlandPraxbindBoehringer Ingelheim International GmbH
- IrelandPraxbind 2.5 g/50 mL solution for injection/infusionBoehringer Ingelheim International GmbH
- IcelandPraxbindBoehringer Ingelheim International GmbH*
- NorwayPraxbindBoehringer Ingelheim International GmbH
- PolandPraxbindBoehringer Ingelheim International GmbH
- SwedenPraxbind 50 mg/ml Injektions-/infusionsvätska, lösningBoehringer Ingelheim International GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Praxbind
- Liechtenstein · Praxbind
- Norway · Praxbind
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f94abb82-bf68-4127-aa4b-115e50288274 GET /v1/drugs/f94abb82-bf68-4127-aa4b-115e50288274?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection/infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Praxbind 2.5 g/50 ml",
"name_fr": "Praxbind 2.5 g/50 ml",
"name_nl": "Praxbind 2.5 g/50 ml",
"amp_code": "SAM487777-00",
"strengths": [
"50.0000",
"2.0000",
"25.0000"
],
"pack_count": 1,
"substances": [
"Idarucizumab",
"Sorbitol",
"Polysorbate 20",
"Sodium"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Idarucizumab",
"authorisation_numbers": [
"EU/1/15/1056/001"
]
}See everything about idarucizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.